Aerobic Exercise Effects in Lower Extremity Lymphedema
2026년 7월 22일 업데이트: Sinem Akselim, Bursa Yuksek Ihtisas Training and Research Hospital
Effects of Aerobic Exercise on Ultrasonographic Parameters, Functional Status, Balance, and Quality of Life in Patients With Lower Extremity Lymphedema
Lower extremity lymphedema negatively affects patients' functional status, quality of life, and activities of daily living. Complete decongestive therapy (CDT) is considered the gold-standard conservative treatment for patients with lymphedema. CDT consists of manual lymph drainage (MLD), skin care, compression bandaging, and exercise. Several studies have demonstrated the effectiveness of CDT in patients with lower extremity lymphedema. However, the results of studies investigating the effectiveness of different types of exercise are inconsistent. Moreover, most of these studies have been conducted in patients with upper extremity lymphedema, and the outcome measures have generally been limited to limb circumference measurements and quality of life assessments.
To the best of our knowledge, no previous study has comprehensively evaluated the effects of aerobic exercise on both ultrasonographic parameters (quantitative data) and functional outcomes in patients with lower extremity lymphedema, as planned in the present study. Therefore, this study was designed to contribute to the existing literature by investigating these effects.
연구 개요
상태
상태
아직 모집하지 않음
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
중재적
등록 (추정된)
등록
50
단계
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
연구 연락처
- 이름: Sinem Akselim
- 전화번호: +905336391332
- 이메일: sinemakselim@gmail.com
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Diagnosis of lower extremity lymphedema (unilateral or bilateral)
- Age ≥18 years
- Absence of cognitive impairment
- Provision of written informed consent to participate in the study
Exclusion Criteria:
- Cognitive impairment
- Presence of general contraindications to exercise (e.g., hemodynamic instability, uncontrolled hypertension, decompensated heart failure, recent myocardial infarction, or unstable angina pectoris)
- Presence of neurological diseases affecting the lower extremities that would preclude participation in the exercise program
- Presence of unhealed fractures in the lower extremities preventing exercise therapy
- Active systemic infection or local infection in the treatment area, such as cellulitis, erysipelas, or thrombophlebitis in the lower extremities
- Acute venous thromboembolic events involving the lower extremities
- Heart failure or renal failure that may cause lower extremity edema
- Presence of concomitant lipedema
- Presence of venous insufficiency
- Ongoing chemotherapy or radiotherapy (among patients with malignancy-related lymphedema)
- Pregnancy
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
2
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: control group
participants receive standart complete decongestive therapy including manuel lymph drainage,compression therapy, skin care and exercises
|
manuel lymph drainage, skin care, joint rom exercises, compression
|
|
실험적: exercise group
participants receive complete decongestive therapy combined with an aerobic exercise program
|
manuel lymph drainage, skin care, joint rom exercises, compression
Aerobic exercise using a recumbent cycle ergometer for 20-30 minutes. The exercise intensity will be set to reach 40-60% of the maximum target heart rate reserve. The treatment program will be administered for approximately 1 hour per day, 5 days per week, for a total of 4 weeks (20 sessions). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Kinesiophobia
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Kinesiophobia will be assessed using the validated Turkish version of the Tampa Scale for Kinesiophobia (TSK), a 17-item questionnaire with a total score ranging from 17 to 68.
Change in score from baseline to post-treatment will be evaluated.
Higher scores indicate greater kinesiophobia.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
musculoskeletal ultrasonography- Muscle and Subcutaneous Tissue Thickness
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
All ultrasonographic measurements will be performed by the same experienced examiner under standardized conditions and will be assessed using B-mode ultrasonography. Quadriceps muscle thickness and subcutaneous tissue thickness will be assessed at standardized anatomical landmarks of the anterior thigh. Subcutaneous tissue thickness will be assessed at standardized anatomical sites of the lower limb. Measurements will be recorded in millimeters (mm). Greater thickness indicates increased muscle mass or subcutaneous tissue thickness, respectively. Change in muscle thickness from baseline to post-treatment will be evaluated. |
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
musculoskeletal ultrasonography- Subcutaneous Tissue Echogenicity
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Subcutaneous tissue echogenicity will be assessed by analyzing grayscale intensity values within a defined region of interest using B-mode ultrasonography.
Echogenicity will be quantified in grayscale values (arbitrary units).
Higher values indicate increased echogenicity.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
Balance
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Balance performance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure with a total score ranging from 0 to 56.
Each item is scored on a 5-point scale (0-4), with higher scores indicating better balance.
Change in score from baseline to post-treatment will be evaluated.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
functional mobility
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Functional mobility will be assessed using the Timed Up and Go (TUG) test, which measures the time (in seconds) required to stand up from a chair, walk 3 meters, turn, return, and sit down.
Change in time from baseline to post-treatment will be evaluated.
Higher times indicate poorer functional mobility.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
Lower limb functional status
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Lower limb functional status will be assessed using the Lower Limb Functional Index (LLFI), a 25-item patient-reported outcome measure with a total score ranging from 0 to 100.
Scores are typically expressed as a percentage, with higher scores indicating better functional status.
Change in score from baseline to post-treatment will be evaluated.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
fatigue
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Fatigue severity will be assessed using the Fatigue Severity Scale (FSS), a 9-item self-reported questionnaire with each item scored from 1 to 7. The total score is calculated as the mean of the items, ranging from 1 to 7, with higher scores indicating greater fatigue severity.
Change in score from baseline to post-treatment will be evaluated.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
depression
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Depression will be assessed using the Beck Depression Inventory (BDI), a 21-item self-reported questionnaire with a total score ranging from 0 to 63.
Higher scores indicate more severe depressive symptoms.
Change in score from baseline to post-treatment will be evaluated.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
|
health related quality of life
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Lymphedema-related quality of life will be assessed using the Lymphedema Quality of Life Questionnaire (LYMQOL), a disease-specific patient-reported outcome measure including domains such as function, appearance, symptoms, and mood.
Domain scores and overall score range from 0 to 10, with higher scores indicating worse quality of life.
Change in scores from baseline to post-treatment will be evaluated.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
functional capacity
기간: baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
Functional exercise capacity will be assessed using the 6-Minute Walk Test (6MWT), which measures the distance walked in meters over 6 minutes.
Change in distance from baseline to post-treatment will be evaluated.
Greater distances indicate better functional performance.
|
baseline (before the first rehabilitation session) and immediately after completing 20 sessions of rehabilitation (4 weeks)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
연구 시작
2026년 8월 1일
기본 완료 (추정된)
기본 완료
2026년 12월 15일
연구 완료 (추정된)
연구 완료
2027년 3월 15일
연구 등록 날짜
최초 제출
최초 제출
2026년 3월 12일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 7월 22일
처음 게시됨 (실제)
처음 게시됨
2026년 7월 24일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 7월 24일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 22일
마지막으로 확인됨
마지막으로 확인됨
2026년 7월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- 2024-TBEK-2025/12-15
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .